Status:
UNKNOWN
A Phase I Single- and Multiple- Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy Subjects
Lead Sponsor:
Shandong Suncadia Medicine Co., Ltd.
Conditions:
Healthy Subjects
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single ascending dose (Part A) and multiple ascending dose...
Eligibility Criteria
Inclusion
- Must be 18 to 55 years of age (inclusive) healthy male or female of nonchildbearing potential;
- Body weight of at least 50 kg for male, and 45 kg for female; and Body Mass Index (BMI) within the range of 19 to 28 kg/m2 (inclusive);
- Subjects (including partners) of childbearing potential are willing to use protocol specified effective methods of contraception from screening to at least 6 months after the final dose of study drug;
- Able and willing to provide written informed consent and to comply with the study protocol;
- Physical examination, vital signs are normal or are judged not clinically significant by the investigator;
Exclusion
- Participants with any abnormal results and judged clinically significant by the investigator;
- HbA1c ≥6.2%, fasting blood-glucose ≤3.9mmol/L (70mg/dL) or ≥6.1mmol/L(110mg/dL) at screening ;
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2 x ULN; total bilirubin ≥1.5 x ULN at screening;
- Abnormal ECG that is clinically significant, or QTcF \>450 msec;
- Positive test result of any of the following at screening: hepatitis B surface antigen (HBsAg), hepatitis C antibody, syphilis, or human immunodeficiency virus (HIV) antibody;
- Any malignancy (except basal cell carcinoma and squamous cell carcinoma of the skin) in the previous 5 years;
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, history of pancreatitis or symptomatic gallbladder disease;
- History of gastric emptying anomalies (gastric outlet obstruction), severe chronic gastrointestinal diseases (such as inflammatory bowel disease, active ulcer) ;
- Subject with major medical history of heart, liver, kidney, endocrine, digestive, blood, respiratory and genitourinary system or existing diseases of the above systems;
- Use any prescription drugs, non-prescription drugs, food supplements, vitamins and Chinese herbal medicines within 2 weeks before administration;
- Subject who received bariatric surgery or procedures, or use of weight-reducing drugs within 3 months prior to administration, or body weight change of more than ±10% within 3 months prior to administration;
- Use any drugs that may affect glucose metabolism were used within 1 month before administration.
- Suspected allergy to any ingredient in the study drug;
- Participation in clinical trials of any drug or medical device within 3 months before screening;
- History of regular alcohol consumption exceeding 14 drinks per week within 6 months before screening;
- More than 5 cigarettes per day or cigarettes within 3 months before screening;
- Subjects who consume alcoholic beverages, Seville oranges, grapefruit or juices, or products containing caffeine or xanthine (such as coffee, tea, cola drinks and chocolate) from 2 days before the start of study treatment;
- Strenuous exercise in 48 hours before treatment;
- Subjects with a history of drug abuse, drug dependence, or a positive drugs of abuse test, or a positive alcohol breath test before study drug administration;
- Donation or loss of blood of ≥ 200 mL within 1 month or of ≥ 400 mL within 3 months prior to the first dose of study drug;
- Subjects can't tolerate venipuncture;
- Subjects have special dietary requirements and cannot comply with the unified diet;
- Other conditions judged by the investigator to be not suitable to participate in the trial;
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 15 2023
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT05347758
Start Date
May 1 2022
End Date
March 15 2023
Last Update
April 26 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.